The NIH Grant With No Money In It: PAR-27-069 Opens 14.7 Million Biospecimens on an October 30 Receipt Date
October 5, 2026 · 7 min read
Granted Research Team · Editorial policy
There is a Notice of Funding Opportunity sitting on Grants.gov right now with an award ceiling of zero dollars.
It is PAR-27-069, Accelerating Discovery through Partnered Research with All of Us to Analyze Participant Biospecimens (X01 Clinical Trial Not Allowed). The next receipt date is October 30, 2026, with one more on March 1, 2027 before the announcement expires on March 2, 2027. It carries no funds whatsoever.
What it carries instead is access to the largest consented, broadly available human biobank in the United States: over 14.7 million aliquoted biospecimens donated by more than 613,000 participants, stored at the All of Us Biobank at Mayo Clinic in Rochester, Minnesota.
Most investigators who stumble across this NOFO misread it in the first thirty seconds, because every instinct trained by R01s and R21s says the number in the budget field is the point. Here the number is zero and the point is the freezer.
What an X01 actually is
The X01 is a Resource Access Award. NIH uses it when the thing being competed for is a research resource rather than a dollar amount — in this case, physical specimens plus a formal partnered-research relationship with the All of Us Research Program.
Read the mechanism plainly: PAR-27-069 provides "access to NIH research resources, rather than direct research funding." You win the right to receive vials. Everything downstream of the vials is yours to pay for.
Three specimen types are available, up to all three per participant:
| Specimen | Collection detail |
|---|---|
| Serum | BD vacutainer serum separation tubes (SST) |
| Plasma | BD vacutainer plasma separation tubes (PST) or EDTA tubes |
| Genomic DNA | Extracted from blood or saliva |
The current subsets are substantial in their own right: more than 593,000 participants with genomic DNA, 488,000 with plasma, and 469,000 with serum. All of Us publishes a biospecimen table — and a subset of it built specifically for X01 applicants — so you can test cohort feasibility before writing a word.
The requirement that inverts the usual order
Here is the clause that disqualifies more applicants than any scientific weakness: you must submit evidence of existing funding, or a plan to secure funding within one year.
Every other NIH application you have written runs in one direction — you describe the work, and NIH decides whether to pay for it. PAR-27-069 runs the other way. You must demonstrate you can already pay for it, and then NIH decides whether to hand over the material.
Specifically, the applicant covers:
- Staff time and effort
- Any required agreements and legal review
- Biospecimen shipping, which the program notes varies for international recipients
- The assays themselves
- Data curation and formatting
- Participation in return-of-value activities
For a multiomics panel across even a few thousand participants, that is not a rounding error. Plasma proteomics at scale, targeted metabolomics, or methylation arrays on tens of thousands of samples routinely run into seven figures before a single analyst is hired.
This creates an obvious chicken-and-egg problem. An R01 study section wants to know you have secured specimen access. The X01 wants to know you have secured money. The program resolves it explicitly by accepting a plan to secure funding within one year — which means the correct sequencing for most academic labs is to submit the X01 concurrently with the R01 and point the X01 at the pending application. Do not wait for the R01 notice of award and then discover the X01 has expired.
Who is actually eligible — and it is broader than you expect
The eligibility list is unusually wide for an NIH announcement:
- Public and private institutions of higher education
- Nonprofits with and without 501(c)(3) status
- For-profit organizations, including small businesses
- State, local, tribal governments and tribal organizations
- Faith-based and community-based organizations
- Foreign organizations and foreign components
A biotech company or a non-U.S. institute can, in principle, obtain access to a 613,000-participant U.S. cohort for the cost of shipping and assays. What it cannot obtain is exclusivity — and that constraint is the heart of the deal.
The one hard exclusion: projects proposing clinical trials are ineligible. The maximum project period is three years.
The nine-month clock is the real price
In exchange for access, you must return curated, research-ready biospecimen assay data to the All of Us Researcher Workbench when your work concludes. You are not simply borrowing specimens; you are commissioned to enlarge the dataset.
Authors receive exclusive access to their own generated data for nine months before it releases to the broad research community. And the obligation goes beyond a data dump. You must also produce researcher-facing materials — support articles, data dictionaries and code examples — so the next investigator can use what you made.
Build your publication calendar backward from that. The embargo attaches to the data, not to your manuscript. If your assay run takes fourteen months and your first paper takes another ten, the nine months of exclusivity have long since burned off by the time you submit. Labs that treat the X01 as a path to a protected dataset will be disappointed. Labs that treat it as a path to being first by a few quarters on a cohort nobody else can assemble will get what they came for.
Two more structural constraints worth putting in front of your IRB and your communications team early:
- Participants receive aggregate-level information only. Returning individual results to participants is prohibited under this award. Do not design an assay whose value proposition is actionable individual feedback.
- A Resource Sharing Plan is required, alongside Specific Aims and a six-page Research Strategy.
What the Research Strategy has to carry
Six pages is tight for what the review criteria ask you to cover. The strategy must address significance and alignment with the All of Us mission, investigator qualifications including demonstrated familiarity with the All of Us Researcher Workbench, biospecimen characteristics and assay validation, laboratory capacity for high-throughput processing, sample size and power calculations, a statistical analysis plan, a return-of-value strategy, and privacy and security protections.
Two of those deserve emphasis because they are where reviewers separate serious applications from hopeful ones.
Volume justification. You must provide scientific justification for the type and volume of serum or plasma requested, because assay requirements differ by sensitivity. Reviewers are explicitly cast as stewards of a finite, irreplaceable resource — every microliter you take is gone for every future study. An application that requests generous volumes "to allow flexibility" is telling the panel you have not validated your assay. Request the volume your validated protocol needs, cite the validation, and say so.
Workbench familiarity. This is a named criterion, not a courtesy. If no one on your team has an All of Us Researcher Workbench account and a demonstrable history on the platform, fix that before October 30 rather than asserting enthusiasm in the biosketch.
The calendar problem nobody is flagging
Look again at the dates. Receipt dates were July 1, 2026, then October 30, 2026, then March 1, 2027 — and the announcement expires March 2, 2027, one day after the last one.
That is a three-cycle announcement with no published successor. It may well be reissued; NIH reissues productive PARs routinely. But planning on a fourth bite is planning on an assumption. If your cohort is defined and your funding story is credible, October 30 is the receipt date to use, because it is the last one that leaves room for a resubmission at the March 1 date if the first attempt comes back with fixable weaknesses. Miss October 30 and your only remaining shot is a one-and-done.
The practical read
PAR-27-069 is not a grant in the sense most people mean. It is a licence to spend your own money on an asset you could not otherwise buy. That makes it a poor fit for an unfunded investigator with a good idea and an excellent fit for three specific profiles:
- A funded lab with an active R01 or program project whose aims already contemplate large-cohort biomarker work, where the specimens are the missing input rather than the missing budget.
- A core facility or assay consortium with instrument capacity standing idle and a credible high-throughput pipeline, for whom the marginal cost per sample is low.
- A company with internal R&D budget that values a nine-month head start on a half-million-participant cohort more than it values permanent exclusivity it was never going to get.
If you are not one of those three, the honest move is to spend October building the funding case instead — then come back. The biobank is being added to continuously, and 14.7 million aliquots is a floor, not a ceiling.
For investigators tracking how NIH is restructuring its announcement architecture more broadly, the parent R25 consolidation and the plain-language MIRA redesign are the same institutional impulse pointed at different mechanisms: fewer, clearer, more standardized front doors. The X01 is the odd one out — a door with no money behind it, and a line forming anyway.